Seres Therapeutics Management
Management criteria checks 3/4
Seres Therapeutics' CEO is Eric Shaff, appointed in Jan 2019, has a tenure of 5.83 years. total yearly compensation is $3.16M, comprised of 21.7% salary and 78.3% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $131.37K. The average tenure of the management team and the board of directors is 5.2 years and 8.2 years respectively.
Key information
Eric Shaff
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 21.7% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.2yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding
Nov 15
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Sep 23Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth
Jul 13Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth
May 08Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Seres Therapeutics: What The Market Is Missing
Aug 19Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M
Aug 03Seres Therapeutics: The Good And The Challenging
Jul 12Seres Therapeutics stock slips on $100M stock offering
Jun 30Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?
Jun 16Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens
Jun 09Seres Therapeutics Is Playing A Long Game
Mar 06Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt
Dec 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$68m |
| Jun 30 2024 | n/a | n/a | -US$162m |
| Mar 31 2024 | n/a | n/a | -US$83m |
| Dec 31 2023 | US$3m | US$685k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$224m |
| Jun 30 2023 | n/a | n/a | -US$153m |
| Mar 31 2023 | n/a | n/a | -US$265m |
| Dec 31 2022 | US$4m | US$662k | -US$250m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$87m |
| Dec 31 2021 | US$10m | US$625k | -US$66m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$132m |
| Mar 31 2021 | n/a | n/a | -US$105m |
| Dec 31 2020 | US$3m | US$590k | -US$89m |
| Sep 30 2020 | n/a | n/a | -US$90m |
| Jun 30 2020 | n/a | n/a | -US$76m |
| Mar 31 2020 | n/a | n/a | -US$66m |
| Dec 31 2019 | US$2m | US$540k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$73m |
| Jun 30 2019 | n/a | n/a | -US$78m |
| Mar 31 2019 | n/a | n/a | -US$95m |
| Dec 31 2018 | US$1m | US$435k | -US$99m |
| Sep 30 2018 | n/a | n/a | -US$107m |
| Jun 30 2018 | n/a | n/a | -US$92m |
| Mar 31 2018 | n/a | n/a | -US$92m |
| Dec 31 2017 | US$2m | US$377k | -US$89m |
Compensation vs Market: Eric's total compensation ($USD3.16M) is above average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Shaff (48 yo)
5.8yrs
Tenure
US$3,158,336
Compensation
Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.8yrs | US$3.16m | 0.10% $ 131.4k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$1.57m | 0.019% $ 25.0k | |
| Executive VP and Chief Commercial & Strategy Officer | 4.4yrs | US$1.82m | 0.053% $ 69.7k | |
| Executive VP & CFO | less than a year | no data | no data | |
| Executive VP & Chief Technology Officer | 4.1yrs | US$5.32m | 0.046% $ 59.8k | |
| Executive VP & Chief Scientific Officer | 5.8yrs | US$1.67m | 0.046% $ 60.0k | |
| Investor Relations Officer | 9yrs | no data | no data | |
| Chief Legal Officer | 8.5yrs | US$1.44m | 0.079% $ 104.2k | |
| Assistant General Counsel | no data | no data | no data |
5.2yrs
Average Tenure
57yo
Average Age
Experienced Management: MCRB's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.8yrs | US$3.16m | 0.10% $ 131.4k | |
| Independent Director | 7.3yrs | US$225.23k | 0.019% $ 24.5k | |
| Independent Director | 9.6yrs | US$222.27k | 0% $ 0 | |
| Independent Director | 9yrs | US$219.23k | 0% $ 0 | |
| Independent Director | 10.1yrs | US$232.69k | 0.037% $ 48.9k | |
| Member of Scientific Advisory Board | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.7yrs | US$211.73k | 0.028% $ 36.7k | |
| Independent Chairman | 5.3yrs | US$249.23k | 0.0021% $ 2.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.2yrs
Average Tenure
63yo
Average Age
Experienced Board: MCRB's board of directors are considered experienced (8.2 years average tenure).